指南与共识肿瘤 PET/CT核素与放射性配体治疗

EANM/SNMMI/ANZSNM联合实践指南/操作标准:实体瘤患者免疫调节治疗期间[18F]FDG PET/CT成像推荐使用版本1.0

Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0.
指南 / 共识 · Eur J Nucl Med Mol Imaging · 2022-04-04

该指南由EANM、SNMMI和ANZSNM合作制定,旨在协助核医学医师、肿瘤科医师等在接受免疫治疗的肿瘤患者中推荐使用[18F]FDG PET/CT,重点关注实体瘤的疗效评估。指南就临床适应证、推荐成像程序和报告标准达成共识并汇总,强调免疫肿瘤学领域快速发展,该文件应作为指导性文件而非确定性标准,并应考虑本地化调整。

要点

  • 本指南由EANM、SNMMI和ANZSNM联合制定,聚焦实体瘤免疫治疗中的[18F]FDG PET/CT应用。
  • 指南就临床适应证、推荐成像程序和报告标准达成共识。
  • 该文件为指导性文件,非确定性标准,应考虑本地化调整。

核心结论

  • 免疫肿瘤学领域快速发展,本指南应视为标准化免疫治疗期间[18F]FDG PET/CT使用与解读的指导文件,而非确定性标准,并应考虑本地化调整。

研究设计与样本

  • 由EANM、SNMMI和ANZSNM合作制定,经广泛评审的共识过程形成,并得到国际专家支持,汇总了EANM肿瘤与诊疗委员会及炎症与感染委员会、SNMMI操作标准委员会的观点。

关键数值与推荐

  • 指南就临床适应证、推荐成像程序和报告标准达成共识并汇总。

临床怎么用

  • 本指南旨在协助核医学医师、其他核医学专业人员、肿瘤科医师或其他医学专家在接受免疫治疗的肿瘤患者中推荐使用[18F]FDG PET/CT,特别关注实体瘤的疗效评估。

局限性

  • 该文件应视为指导文件而非确定性标准,并应考虑本地化调整。
  • 指南为基于当前知识的共识文件,不意图作为硬性规则或实践要求,也不应用于确立法律护理标准。
  • 遵循这些标准/指南不能确保成功结果。
  • 指南推荐不应替代国家和国际法律或法规规定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The goal of this guideline/procedure standard is to assist nuclear medicine physicians, other nuclear medicine professionals, oncologists or other medical specialists for recommended use of [18F]FDG PET/CT in oncological patients undergoing immunotherapy, with special focus on response assessment in solid tumors. METHODS: In a cooperative effort between the EANM, the SNMMI and the ANZSNM, clinical indications, recommended imaging procedures and reporting standards have been agreed upon and summarized in this joint guideline/procedure standard. CONCLUSIONS: The field of immuno-oncology is rapidly evolving, and this guideline/procedure standard should not be seen as definitive, but rather as a guidance document standardizing the use and interpretation of [18F]FDG PET/CT during immunotherapy. Local variations to this guideline should be taken into consideration. PREAMBLE: The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association founded in 1985 to facilitate worldwide communication among individuals pursuing clinical and academic excellence in nuclear medicine. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote science, technology and practical application of nuclear medicine. The Australian and New Zealand Society of Nuclear Medicine (ANZSNM), founded in 1969, represents the major professional society fostering the technical and professional development of nuclear medicine practice across Australia and New Zealand. It promotes excellence in the nuclear medicine profession through education, research and a commitment to the highest professional standards. EANM, SNMMI and ANZSNM members are physicians, technologists, physicists and scientists specialized in the research and clinical practice of nuclear medicine. All three societies will periodically put forth new standards/guidelines for nuclear medicine practice to help advance the science of nuclear medicine and improve service to patients. Existing standards/guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated. Each standard/guideline, representing a policy statement by the EANM/SNMMI/ANZSNM, has undergone a thorough consensus process, entailing extensive review. These societies recognize that the safe and effective use of diagnostic nuclear medicine imaging requires particular training and skills, as described in each document. These standards/guidelines are educational tools designed to assist practitioners in providing appropriate and effective nuclear medicine care for patients. These guidelines are consensus documents based on current knowledge. They are not intended to be inflexible rules or requirements of practice, nor should they be used to establish a legal standard of care. For these reasons and those set forth below, the EANM, SNMMI and ANZSNM caution against the use of these standards/guidelines in litigation in which the clinical decisions of a practitioner are called into question. The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by medical professionals considering the unique circumstances of each case. Thus, there is no implication that an action differing from what is laid out in the guidelines/procedure standards, standing alone, is below standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the standards/guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources or advances in knowledge or technology subsequent to publication of the guidelines/procedure standards. The practice of medicine involves not only the science, but also the art of dealing with the prevention, diagnosis, alleviation and treatment of disease. The variety and complexity of human conditions make it impossible for general guidelines to consistently allow for an accurate diagnosis to be reached or a particular treatment response to be predicted. Therefore, it should be recognized that adherence to these standards/ guidelines will not ensure a successful outcome. All that should be expected is that practitioners follow a reasonable course of action, based on their level of training, current knowledge, clinical practice guidelines, available resources and the needs/context of the patient being treated. The sole purpose of these guidelines is to assist practitioners in achieving this objective. The present guideline/procedure standard was developed collaboratively by the EANM, the SNMMI and the ANZSNM, with the support of international experts in the field. They summarize also the views of the Oncology and Theranostics and the Inflammation and Infection Committees of the EANM, as well as the procedure standards committee of the SNMMI, and reflect recommendations for which the EANM and SNMMI cannot be held responsible. The recommendations should be taken into the context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, et al. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging. 2022. PMID: 35376991. doi:10.1007/s00259-022-05780-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。